Alector Announces Licensing Agreement for Parkinson's Treatment Program
Alector (ALEC) shares rose approximately 22% in early Monday trading following an announcement of a licensing agreement with Genentech, which is owned by Roche. The deal involves Alector’s AL050 program aimed at treating Parkinson’s and other neurodegenerative diseases. Under the terms of the agreement, Genentech has been granted global rights to develop and commercialize AL050. This partnership could provide a significant boost for Alector by offloading development responsibilities while securing financial compensation or future milestone payments.
